Peer review reports
From: Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial
Original Submission |
10 Jun 2020 |
Submitted |
Original manuscript
|
30 Dec 2020 |
Author responded |
Author comments - Eli Mansour
|
Resubmission - Version 2 |
30 Dec 2020 |
Submitted |
Manuscript version 2
|
Publishing |
6 Jan 2021 |
Editorially accepted |
|
20 Jan 2021 |
Article published |
10.1186/s13063-021-05027-9
|
Learn about peer review